Extracorporeal Photoimmunotherapy for Circulating Tumor Cells
Abstract
It is believed that metastasis through the cardiovascular system is primarily caused by circulating tumor cells (CTCs). We report an approach to eliminate circulating tumor cells from the blood stream by flowing the blood though an extracorporeal tube and applying photodynamic therapy (PDT). Chlorin e6 (Ce6), a photosensizer, was conjugated to antibody CD44 in order to target PC-3, a prostate cancer cell line. PC-3 cells were successfully stained by the Ce6-CD44 antibody conjugate. PDT was performed on whole blood spiked with stained PC-3 cells. As the blood circulated through a transparent medical tube, it was exposed to light of a specific wavelength generated by an LED array. A 2 minute exposure was sufficient to achieve selective cancer cell necrosis. Control studies showed no cell death.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Highly efficient, all-organic bioluminescence-photosensitizer conjugate eradicates early-stagetumors and prevents metastasis in mice
H. Yan, S. Forward, … S.-H. Yun·bioRxiv·Jan 29, 2022
- CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
- Light-controlled elimination of PD-L1+ cells
J. J. W. Wong, P. K. Selbo·bioRxiv·Aug 13, 2021
- Fast label-free live imaging reveals key roles of flow dynamics and CD44-HA interaction in cancer cell arrest on endothelial monolayers
Gautier Follain, Sujan Ghimire, … Guillaume Jacquemet·The EMBO JournalPeer-reviewed·Jan 6, 2026
- Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
A. P. Bidkar, S. Wang, … R. R. Flavell·bioRxiv·Oct 13, 2022
- Tumor irradiation combined with vascular-targeted photodynamic therapy enhances anti-tumor effects in preclinical prostate cancer.
H. T. Sjoberg, Y. J. Philippou, … R. J. Bryant·bioRxiv·Nov 26, 2020